Market revenue in 2020 | USD 42.0 million |
Market revenue in 2028 | USD 109.7 million |
Growth rate | 12.7% (CAGR from 2020 to 2028) |
Largest segment | Lymphoma |
Fastest growing segment | Lymphoma |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Leukemia, Lymphoma, MPNs, Other Cancers |
Key market players worldwide | Roche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.
Lymphoma was the largest segment with a revenue share of 46.19% in 2020. Horizon Databook has segmented the Australia hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.
Increasing government initiatives to improve diagnosis rate of blood cancer in the region is anticipated to significantly support the market growth over the forecast period. For instance, in September 2019, the Australian Government announced to establish a National Action Plan to improve diagnosis and treatment of blood cancers in the region.
In February 2019, the Federal Government of Australia granted USD 1.3 million in funds to establish a multi-disciplinary blood cancer clinic to screen families at risk of lymphoma and leukemia. In addition, as part of 2020/2021 Budget, the Morrison Government has planned to offer more than USD 600,000 to the Foundation of Leukaemia as a part of the country’s first National Strategic Plan for Blood Cancer.
Moreover, blood cancers, comprising lymphoma, leukemia, and myeloma are projected to account for more than 1 in 10 cancer demises in Australia in 2020. Furthermore, the number of blood cancers identified each year is increasing; from around 12,500 cases in 2010 to 17,300 in 2020 and it is projected that there will be around 5,600 deaths from blood cancer in 2020.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into Australia hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account